Lipopolysaccharide and tumor necrosis factor alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression

Journal of Virology

Volumn 90, Issue 12, 2016, Pages 5549-5560

  MacParland, Sonya A ^a   Ma, Xue Zhong ^a   Chen, Limin ^a,b   Khattar, Ramzi ^a   Cherepanov, Vera ^c   Selzner, Markus ^a   Feld, Jordan J ^c,d   Selzner, Nazia ^a   McGilvray, Ian D ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b INSTITUTE OF BLOOD TRANSFUSION   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYXOVIRUS RESISTANCE PROTEIN; PROTEIN MX1; PROTEIN USP18; PROTEINASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; UBIQUITIN THIOLESTERASE; USP18 PROTEIN, HUMAN; USP18 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE EXPRESSION REGULATION; GENE SILENCING; HEPATITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER CELL; LYMPHOCYTIC CHORIOMENINGITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS REPLICATION; ANIMAL; BLOOD; CHRONIC HEPATITIS C; GENETICS; HEPACIVIRUS; IMMUNOLOGY; INFLAMMATION; INJURIES; ISCHEMIA; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION; VIROLOGY;

ANIMALS; CELL LINE, TUMOR; ENDOPEPTIDASES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-6; ISCHEMIA; LIPOPOLYSACCHARIDES; LIVER; MICE; MYXOVIRUS RESISTANCE PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN THIOLESTERASE;

EID: 84971475367     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02557-15     Document Type: Article

References (56)

1. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972. http://dx.doi.org/10.1038/nature04082.
2. Haller O, Kochs G, Weber F. 2007. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev 18:425-433. http://dx.doi.org/10.1016/j.cytogfr.2007.06.001.
3. Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K. 2013. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 87:8169-8178. http://dx.doi.org/10.1128/JVI.00974-13.
4. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. 1996. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23:210-217. http://dx.doi.org/10.1002/hep.510230203.
5. Zein NN, The Etanercept Study Group. 2005. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebocontrolled study. J Hepatol 42:315-322. http://dx.doi.org/10.1016/j.jhep.2004.11.025.
6. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G, The GISEA Group. 2008. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitisCvirus infection. J Rheumatol 35:1944-1949.
7. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch K. 2012. Hepatic celltype specific gene expression better predictsHCVtreatment outcome than IL28B genotype. Gastroenterology 142:1122-1131. http://dx.doi.org/10.1053/j.gastro.2012.01.028.
8. Chen LM, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. 2005. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437-1444. http://dx.doi.org/10.1053/j.gastro.2005.01.059.
9. Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID. 2010. Cell-type-specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138:1123-U1415. http://dx.doi.org/10.1053/j.gastro.2009.10.046.
10. Lang PA, Recher M, Honke N, Scheu S, Borkens S, Gailus N, Krings C, Meryk A, Kulawik A, Cervantes-Barragan L, Van Rooijen N, Kalinke U, Ludewig B, Hengartner H, Harris N, Haeussinger D, Ohashi PS, Zinkernagel RM, Lang KS. 2010. Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-Idependent manner in mice. Hepatology 52:25-32. http://dx.doi.org/10.1016/j.jhep.2009.10.003.
11. Boltjes A, Movita D, Boonstra A, Woltman AM. 2014. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol 61:660-671. http://dx.doi.org/10.1016/j.jhep.2014.04.026.
12. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, Zhang DE, Heim MH. 2009. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29:4841-4851. http://dx.doi.org/10.1128/MCB.00224-09.
13. Chen L, Li S, McGilvray I. 2011. The ISG15/USP18 ubiquitin-like pathway (ISGylation system) in hepatitis C virus infection and resistance to interferon therapy. Int J Biochem Cell Biol 43:1427-1431. http://dx.doi.org/10.1016/j.biocel.2011.06.006.
14. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J, Rice CM, Edwards AM, McGilvray ID. 2006. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131:1584-1591. http://dx.doi.org/10.1053/j.gastro.2006.08.043.
15. Malakhova OA, Kim KI, Luo J-K, Zou W, Kumar KGS, Fuchs SY, Shuai K, Zhang D-E. 2006. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25:2358-2367. http://dx.doi.org/10.1038/sj.emboj.7601149.
16. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, Pellegrini S, Uze G. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 6:e22200. http://dx.doi.org/10.1371/journal.pone.0022200.
17. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S, Tanaka N, Taniguchi T. 2001. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 283:1150-1156. http://dx.doi.org/10.1006/bbrc.2001.4913.
18. Malakhova O, Malakhov M, Hetherington C, Zhang DE. 2002. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem 277:14703-14711. http://dx.doi.org/10.1074/jbc.M111527200.
19. Perry BC, Soltys D, Toledo AH, Toledo-Pereyra LH. 2011. Tumor necrosis factor-alpha in liver ischemia/reperfusion injury. J Investig Surg 24:178-188. http://dx.doi.org/10.3109/08941939.2011.568594.
20. Nolan JP. 2010. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 52:1829-1835. http://dx.doi.org/10.1002/hep.23917.
21. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G. 2007. Viral and host factors induce macrophage activation and loss of Toll-like receptor tolerance in chronic HCV infection. Gastroenterology 133:1627-1636. http://dx.doi.org/10.1053/j.gastro.2007.08.003.
22. Honke N, Shaabani N, Cadeddu G, Sorg UR, Zhang D-E, Trilling M, Klingel K, Sauter M, Kandolf R, Gailus N, van Rooijen N, Burkart C, Baldus SE, Grusdat M, Loehning M, Hengel H, Pfeffer K, Tanaka M, Haeussinger D, Recher M, Lang PA, Lang KS. 2012. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 13:51-57. http://dx.doi.org/10.1038/ni.2169.
23. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
24. Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, Nozawa Y, Nakashima S, Moriwaki H. 2001. TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J Immunol 167:173-180. http://dx.doi.org/10.4049/jimmunol.167.1.173.
25. Chung B, Verdier F, Matak P, Deschemin J-C, Mayeux P, Vaulont S. 2010. OncostatinMis a potent inducer of hepcidin, the iron regulatory hormone. FASEB J 24:2093-2103. http://dx.doi.org/10.1096/fj.09-152561.
26. Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, Sebolao B, Tran A, Spelman T, Matthews G, Cameron P, Tangkijvanich P, Dore GJ, Ruxrungtham K, Lewin SR. 2014. Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. J Infect Dis 210:745-751. http://dx.doi.org/10.1093/infdis/jiu119.
27. Ma XZ, Bartczak A, Zhang JH, He W, Shalev I, Smil D, Chen LM, Phillips J, Feld JJ, Selzner N, Levy G, McGilvray I. 2014. Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol 88: 6195-6204. http://dx.doi.org/10.1128/JVI.03801-13.
28. MacParland SA, Pham TNQ, Guy CS, Michalak TI. 2009. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 49:1431-1441. http://dx.doi.org/10.1002/hep.22802.
29. Glass DB, Lundquist LJ, Katz BM, Walsh DA. 1989. Protein-kinase inhibitor-(6-22)-amide peptide analogs with standard and nonstandard amino-acid substitutions for phenylalanine-10: inhibition of campdependent protein-kinase. J Biol Chem 264:14579-14584.
30. Zhu LM, Cheng XJ, Ding YF, Shi JD, Jin HY, Wang H, Wu YL, Ye J, Lu YM, Wang TC, Yang CS, Tu SP. 2014. Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett 343:80-89. http://dx.doi.org/10.1016/j.canlet.2013.09.017.
31. Yuen SL, Ogut O, Brozovich FV. 2009. Nonmuscle myosin is regulated during smooth muscle contraction. Am J Physiol Heart Circ Physiol 297: H191-H199. http://dx.doi.org/10.1152/ajpheart.00132.2009.
32. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. 1995. PD-098059 is a specific inhibitor of the activation of mitogen-activated protein-kinase kinase in-vitro and in-vivo. J Biol Chem 270:27489-27494. http://dx.doi.org/10.1074/jbc.270.46.27489.
33. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. 2002. Silibinin inhibits constitutive and TNF alpha-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNF alpha-induced apoptosis. Oncogene 21:1759-1767. http://dx.doi.org/10.1038/sj.onc.1205240.
34. Arcaro A, Wymann MP. 1993. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 296:297-301. http://dx.doi.org/10.1042/bj2960297.
35. Selzner N, Rudiger H, Graf R, Clavien PA. 2003. Protective strategies against ischemic injury of the liver. Gastroenterology 125:917-936. http://dx.doi.org/10.1016/S0016-5085(03)01048-5.
36. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12:1301-1309. http://dx.doi.org/10.1038/nm1492.
37. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, Zinkernagel RM. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-well or 96-well plates. J Virological Methods 33:191-198. http://dx.doi.org/10.1016/0166-0934(91)90018-U.
38. Silverman N, Fitzgerald K. 2004. DUBbing down innate immunity. Nat Immunol 5:1010-1012. http://dx.doi.org/10.1038/ni1004-1010.
39. Rui L, Schmitz R, Ceribelli M, Staudt LM. 2011. Malignant pirates of the immune system. Nat Immunol 12:933-940. http://dx.doi.org/10.1038/ni.2094.
40. Anderson L, Seilhamer J. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18:533-537. http://dx.doi.org/10.1002/elps.1150180333.
41. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT. 2014. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59: 1250-1261. http://dx.doi.org/10.1002/hep.26653.
42. Luedde T, Schwabe RF. 2011. NF-κB in the liver-linking injury, fibrosis, and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8:108-118. http://dx.doi.org/10.1038/nrgastro.2010.213.
43. Neuman UP, Biermer M, Eurich D, Neuhaus P, Berg T. 2010. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 52:951-952. http://dx.doi.org/10.1016/j.jhep.2010.02.002.
44. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pecheur EI, Tavis JE, Polyak SJ. 2011. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 6:e16464. http://dx.doi.org/10.1371/journal.pone.0016464.
45. Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM. 2000. Dexamethasone inhibits IL-1β gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-κB/Rel and AP-1 activation. Immunopharmacology 48:173-183. http://dx.doi.org/10.1016/S0162-3109(00)00199-5.
46. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, Gray JG. 1994. NF-κB regulates IL-1β transcription through a consensus NF-κB binding site and a nonconsensus Cre-like site. J Immunol 153:712-723.
47. Liu X, Li H, Zhong B, Blonska M, Gorjestani S, Yan M, Tian Q, Zhang D-E, Lin X, Dong C. 2013. USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J Exp Med 210:1575-1590. http://dx.doi.org/10.1084/jem.20122327.
48. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, Akira S. 2005. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6:1087-1095. http://dx.doi.org/10.1038/ni1255.
49. Inokuchi S, Aoyama T, Miura K, Oesterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. 2010. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 107:844-849. http://dx.doi.org/10.1073/pnas.0909781107.
50. Condotta SA, Khan SH, Rai D, Griffith TS, Badovinac VP. 2015. Polymicrobial sepsis increases susceptibility to chronic viral infection and exacerbates CD8+ T cell exhaustion. J Immunol 195:116-125. http://dx.doi.org/10.4049/jimmunol.1402473.
51. Selzner M, Kashfi A, Selzner N, McCluskey S, Greig PD, Cattral MS, Levy GA, Lilly L, Renner EL, Therapondos G, Adcock LE, Grant DR, McGilvray ID. 2009. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transpl 15:1288-1295. http://dx.doi.org/10.1002/lt.21828.
52. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, Clavien PA. 2000. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 6:407-412. http://dx.doi.org/10.1053/jlts.2000.7581.
53. Cherepanov VA, Alvandi Z, Chen LM, Selzner N, Renner EL, McGilvray I, Feld JJ. 2012. The ubiquitin specific protease USP18 is necessary but not sufficient for a hepatocyte IFN refractory state: variable roles in type I and type III IFN responsiveness. Hepatology 56:1103A-1103A.
54. Freitas MC, Uchida Y, Zhao D, Ke B, Busuttil RW, Kupiec-Weglinski JW. 2010. Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl 16:600-610. http://dx.doi.org/10.1002/lt.22036.
55. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P. 2008. Silibinin is a potent antiviral agent in patients with chronic hepatitisCnot responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:1561-1567. http://dx.doi.org/10.1053/j.gastro.2008.07.072.
56. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164-171. http://dx.doi.org/10.1038/ng.2521.